This Article Full Text (PDF) All Versions of this Article: 0272989X08323299v1 29/1/104    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Felli, J. C. Articles by Cavazzoni, P. A. Search for Related Content PubMed PubMed Citation Articles by Felli, J. C. Articles by Cavazzoni, P. A. Pubmed/NCBI databases Medline Plus Health Information Medicines Social Bookmarking                         What's this?

A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives

Eli Lilly & Company, Indianapolis, IN, felli_james_c{at}lilly.com

Rebecca A. Noel, DrPH

Eli Lilly & Company, Indianapolis, IN

Patrizia A. Cavazzoni, MD

Eli Lilly & Company, Indianapolis, IN

The assessment of the benefits and risks associated with a medicine's use requires careful consideration of a wealth of information of varying format and quality, ranging from efficacy and safety data derived from randomized clinical trials to statistical results from health outcomes studies to spontaneously reported adverse events. Contrary to the expectations of patients, physicians, and regulators, the literature offers little guidance as to how to strike an appropriate balance between benefit and risk. Although a qualitative listing of a medicine's benefits and risks is useful, much could be gained from a systematic and transparent process to evaluate a medicine's pre- and postmarketing performance. The authors propose a representational model based on multicriteria decision analysis that can incorporate both evaluative judgments from different perspectives (e.g., physician, patient) and quantitative data to inform tradeoffs between multiple benefit and multiple risk elements in a logically consistent and transparent manner. The model is designed to highlight the relative merits and deficits of treatment alternatives in well-defined and specific contexts. It is intended to serve as a common platform to facilitate focused benefit-risk tradeoff discussions between scientists, physicians, regulatory authorities, and pharmaceutical companies, and to assist in the communication of clear and consistent messages regarding those tradeoffs.

Key Words: Key words: benefit-risk analysis • benefit-risk communication • multiattribute decision analysis • pharmaceutical applications • decision analysis. (Med Decis Making 2009;29:104—115)

This version was published on January 1, 2009

Medical Decision Making, Vol. 29, No. 1, 104-115 (2009)
DOI: 10.1177/0272989X08323299


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?